FXYD6P3

Across TCGA pan-cancer cohorts, FXYD6P3 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated FXYD6P3 data layer compared with 2 for mutation status.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher FXYD6P3 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated FXYD6P3 expression acts as an unfavorable survival marker, although some lineages such as ESCA and UCS show a favorable association.

BLCA, PAAD, and BRCA are the cancer types where FXYD6P3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Tertile	All	0.232	0.639	<.001	99	view →
PAAD	OS	Tertile	All	0.112	0.613	<.001	72	view →
BRCA	DFS	Tertile	III,IV	0.111	0.497	.002	54	view →
LUAD	OS	Tertile	II,III,IV	0.103	0.682	<.001	36	view →
LIHC	DFS	Tertile	All	0.152	0.545	.012	27	view →
UCEC	OS	Tertile	IV	0.308	0.748	.009	18	view →
ESCA	DFS	Tertile	III,IV	0.635	0.364	.029	18	view →
COAD	DFS	Tertile	III,IV	0.170	0.697	.030	18	view →
UCS	DFS	Tertile	II,III,IV	1.000	0.244	.033	12	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

FXYD6P3–BLCA (DFS)

Open the BLCA breakdown →